ESTRO 2024 - Abstract Book

S401

Brachytherapy - Urology

ESTRO 2024

Local control (LC) was 100% and 95% at 5 and 10 years respectively in group 1, 100% and 71% at 5 and 10 years in group 2, 100% at 5 and 10 years in group 3 and 30% at 5 and 10 years in group 4 (p< 0,001). In patients treated with LDR BT, LC was 100% and 98% at 5 and 10 years respectively in group 1, 100% and 53% at 5 and 10 years in group 2, 100% and 50% at 5 and 10 years in group 3 and 0% at 5 years in group 4 (p< 0,001). When HDR BT was employed, LC was 100% in group 1, 2 and 3 and 67% in group 4 at 5 years (p< 0,001). There are no patients of group 1, 2 or 3 with recurrence outside the prostate. Four patients (44%) of group 4 had disease in pelvic lymph nodes (1) and distant metastases (3).

Conclusion:

The nPSA categories provide prognostic information that identifies the patients at increased risk of BF. Reaching low nadir values at a set time point post-BT predicts improved clinical outcomes. Evaluation of nPSA in exclusive BT treatments in low risk and intermediate risk PC provided a very useful tool in the follow-up of these group of patients, in order to establish early rescues strategies.

Keywords: Prostate, Nadir, Brachytherapy

573

Digital Poster

Salvage LDR prostate brachytherapy: a single institution retrospective study

Rebecca L Geary, Meabh McNulty, Geraldine O'Boyle, Anysja Zuchora, Leanne Berrigan, Nazir Ibrahim, Cormac Small

University Hospital Galway, Radiation Oncology, Galway, Ireland

Purpose/Objective:

The aim of the study was to evaluate the safety and efficacy of salvage low dose rate (LDR) brachytherapy for locally recurrent prostate cancer after external beam radiotherapy.

Material/Methods:

A retrospective analysis was performed on all patients who underwent salvage LDR prostate brachytherapy between January 2009 and May 2021 at University Hospital Galway, Ireland. The primary endpoint was the rate of acute and late toxicities. Secondary endpoints included overall survival, progression free survival, biochemical recurrence free survival and androgen-deprivation-therapy free survival which were calculated using the Kaplan Meier method.

Results: